TED: Phenotypic and Genetic Assessment of Tracheal and Esophageal Birth Defects in Patients

Sponsor
Children's Hospital Medical Center, Cincinnati (Other)
Overall Status
Recruiting
CT.gov ID
NCT03455881
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (NIH), Columbia University (Other)
260
1
69.2
3.8

Study Details

Study Description

Brief Summary

The investigators propose a preliminary study performing exome sequencing on samples from patients and their biologically related family members with tracheal and esophageal birth defects (TED). The investigators will use advanced, non-invasive magnetic resonance imaging (MRI) techniques to assess tracheal esophageal, lung, and cardiac morphology and function in Neonatal Intensive Care Unit (NICU) patients. The purpose of this study is to determine if patients diagnosed with TED and similar disorders carry distinct mutations that lead to predisposition and to determine if an MRI is a more effective way of evaluating the TEDs.

Detailed Description

TEDs (tracheal esophageal birth defects) are a life threatening congenital disorder with multiple long term complications. Occurring in 1 in 2,500 to 4,500 live births, TEDs include tracheal malformations such as tracheomalacia, laryngotracheoesophageal clefts, tracheal agenesis, tracheal stenosis, tracheal bronchus, esophageal bronchus and esophageal malformations such as esophageal atresia (EA), tracheal esophageal fistula (TEF), and esophageal duplication. TEDs likely have a genetic basis, but in most cases the specific mutations are unknown. The most commonly diagnosed TED, requiring neonatal hospitalization, is EA/TEF. The familial recurrence rate of EA/TEF is 1% suggesting many result from de novo mutations and while environmental factors may have a minor influence, the mechanisms are unclear. The investigators hypothesize that patients diagnosed with TED and similar disorders carry distinct mutations that lead to predisposition. Currently the diagnosis is confirmed only with a plain chest x-ray showing a coiled feeding tube within the upper esophageal pouch. This approach does not determine the anatomic subtype of EA/TEF, the number or location of TEFs, the size of the gap between proximal and distal esophagus, or the presence of tracheomalacia. Many have evaluated preoperative laryngotracheo-bronchoscopy (LTB) and others have evaluated preoperative computerized tomography (CT) scanning to decrease the unknown factors associated with x-ray, but despite their potential benefits, they have great drawbacks. Therefore, there is a compelling need to develop noninvasive non ionizing imaging methods to evaluate TED infants. Magnetic Resonance Imaging (MRI) is an ideal candidate to fill this role in that it provides non-invasive high resolution anatomic and functional information. Here the investigators propose a preliminary study performing exome sequencing on samples from these patients and their biologically related family members. The investigators will also use advanced, non-invasive MR imaging techniques to assess TE, lung, and cardiac morphology and function in NICU patients.

Study Design

Study Type:
Observational
Anticipated Enrollment :
260 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Comprehensive Phenotypic and Genetic Assessment of Tracheal and Esophageal Birth Defects in Patients
Actual Study Start Date :
Mar 28, 2018
Anticipated Primary Completion Date :
Jan 1, 2023
Anticipated Study Completion Date :
Jan 1, 2024

Arms and Interventions

Arm Intervention/Treatment
NICU TED Genetic Cohort

This study involves one inpatient biofluid collection encounter from the subject, one biofluid collection encounter from each biological parent, and an optional biofluid collection encounter from other biological family members.

NICU TED MRI Cohort

This study involves up to three inpatient NICU MRI encounters. The first MRI may be done before surgical repair if the clinical team feels the infant is clinically stable. The second MRI may be completed post-surgical repair of TED. An additional 3rd MRI may be done prior to the time of discharge from the NICU. The pre repair, post-surgical, and pre discharge MRIs will provide valuable data for the understanding of tracheal esophageal malformation disorders and may provide clinical guidance for the participant's care.

TED Genetic Cohort

This study involves one biofluid collection encounter from the subject, one biofluid collection encounter from each biological parent, and an optional biofluid collection encounter from other biological family members.

NICU Control MRI Cohort

This study involves two inpatient NICU MRI encounters. The first MRI will occur within the first month of life, and the second MRI will occur prior to discharge.

Outcome Measures

Primary Outcome Measures

  1. Genomic Sequencing [1 day]

    Identify novel genes and mutations in patients with TEDs using trio genomic sequencing of TED patients and their parents.

  2. Anatomic phenotypes using MRI [1 day]

    Investigate the esophageal, tracheal, mediastinal and pulmonary anatomy in patients with TEDs.

Secondary Outcome Measures

  1. Change in the anatomic phenotype using MRI [Change in MRI from pre-repair to discharge]

    Investigate the esophageal, tracheal, mediastinal and pulmonary anatomy in patients with TEDs before and after surgical repair.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
NICU TED Genetic Cohort:
Inclusion Criteria:
  • Infant born between 24 and 42 weeks PMA.

  • TED diagnosed by clinical team.

  • Inpatient in the Neonatal Intensive Care Unit (NICU) OR family member to the inpatient in the NICU.

  • Willingness to donate biological specimens.

  • Ability to consent/assent as appropriate.

Exclusion Criteria:
  • Unable to determine or unavailable parent trio.

  • Unable to provide DNA sample.

  • Inability to provide consent.

NICU TED MRI Cohort:
Inclusion Criteria:
  • Infant born between 24 and 42 weeks PMA.

  • TED diagnosed by clinical team.

  • Inpatient in the CCHMC (Cincinnati Children's Hospital Medical Center) NICU.

  • Clinically stable and adequate temperature control to tolerate MRI as determined by the primary clinical team.

  • Infant and biological parents are participating in the NICU TED cohort.

  • Ability to consent/assent as appropriate.

Exclusion Criteria:
  • Infant is on extracorporeal membrane oxygenation (ECMO).

  • Evidence of congenital diseases that may affect ability to tolerate MRI.

  • Standard MRI exclusion criteria as set forth by the CCHMC Department of Radiology. This includes any contraindications from tracheostomy tubes that are not MR compatible.

  • Inability to provide consent.

TED Genetic Cohort:
Inclusion Criteria:
  • Patient that has been diagnosed by clinical team with a congenital TED OR family member to the TED diagnosed patient.

  • Willingness to donate biological specimens.

  • Ability to consent/assent as appropriate.

Exclusion Criteria:
  • Unable to determine or unavailable parent trio.

  • Unable to provide DNA sample.

  • Inability to provide consent.

NICU Control MRI Cohort:
Inclusion Criteria:
  • Infant born between 24 and 42 weeks post menstrual age (PMA).

  • No tracheal or esophageal defects.

  • Inpatient in the CCHMC NICU.

  • Clinically stable and adequate temperature control to tolerate MRI as determined by the primary clinical team.

Exclusion Criteria:
  • Infant is on ECMO.

  • Evidence of congenital diseases that may affect ability to tolerate MRI.

  • Standard MRI exclusion criteria as set forth by the CCHMC Department of Radiology. This includes any contraindications from tracheostomy tubes that are not MR compatible.

  • Inability to provide consent.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cincinnati Children's Hospital Cincinnati Ohio United States 45229

Sponsors and Collaborators

  • Children's Hospital Medical Center, Cincinnati
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • Columbia University

Investigators

  • Principal Investigator: Paul Kingma, MD, PhD, Children's Hospital Medical Center, Cincinnati

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Children's Hospital Medical Center, Cincinnati
ClinicalTrials.gov Identifier:
NCT03455881
Other Study ID Numbers:
  • CIN_PhenoandGeneticTED_001
  • 1P01HD093363-01
First Posted:
Mar 7, 2018
Last Update Posted:
Sep 22, 2020
Last Verified:
Sep 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Children's Hospital Medical Center, Cincinnati
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 22, 2020